Premium
CD8 T‐cell‐mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer
Author(s) -
Hardwick Marc,
Nolan Luke,
Nicoll James A. R.,
Jogai Sanjay,
Arriola Edurne,
JosephPietras Debora,
Norman Jeanette,
Ottensmeier Christian H. H.,
Galea Ian
Publication year - 2022
Publication title -
neuropathology and applied neurobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.538
H-Index - 95
eISSN - 1365-2990
pISSN - 0305-1846
DOI - 10.1111/nan.12755
Subject(s) - paraneoplastic cerebellar degeneration , cytotoxic t cell , cd8 , pathology , ipilimumab , medicine , cd20 , lung cancer , cell , purkinje cell , t cell , cancer research , immune system , antigen , immunology , cerebellum , biology , immunotherapy , antibody , autoantibody , biochemistry , in vitro , genetics
We report a rapidly progressive and fatal CD8 T‐cell‐mediated cerebellitis after ipilimumab (cytotoxic T‐lymphocyte‐associated protein 4 inhibitor) for small cell lung cancer. Clinical features and histopathology were consistent with an accelerated form of paraneoplastic cerebellar degeneration. A patchy CD8 T‐cell infiltrate spatially corresponded to areas of Purkinje cell loss, with occasional CD8 polarisation towards Purkinje cells. CD20‐positive B cells were sparse. CD8 T‐cell‐mediated cerebellitis after immune checkpoint inhibitor treatment may recapitulate the early stages of paraneoplastic cerebellar degeneration.